Premature coronary heart disease (PCHD or PCAD) is caused by abnormal lipid metabolism in the body. A kind of atherosclerotic lipid substance is generated on the smooth intima of the artery. Over time, white plaques are formed, namely acute myocardial infarction (AMI). Acute myocardial infarction is a serious threat to human health. This article took PCAD-AMI patients hospitalized from June 2020 to June 2021 as the research subjects. 80 cases were randomly selected and divided into two groups, with 40 cases in each group. They were evenly allocated to receive treatment with rosuvastatin (group B) and atorvastatin (group A), and their therapeutic effects were statistically analyzed and summarized. In the self-evaluation of patients in groups A and B, both groups had a satisfaction score of no less than 7 points with treatment, and their impact on quality of life was improved. Therefore, the prognosis of PCAD-AMI treated with different statins was relatively good.

Shixin Kang. Clinical Study of Different Statins in the Treatment of Acute Myocardial Infarction in Coronary Heart Disease. Frontiers in Medical Science Research (2024), Vol. 6, Issue 1: 42-48. https://doi.org/10.25236/FMSR.2024.060108.

[1] Jiang Daming and Han Jinjie. Comparison of clinical efficacy between atorvastatin and rosuvastatin in the treatment of early-onset coronary heart disease with acute myocardial infarction. China Pharmaceutical, 2020, 29 (S02): 42-43.

[2] Xu Hui, Liu Fang. Correlation analysis between monocyte count/high-density lipoprotein cholesterol ratio and early-onset coronary heart disease. Journal of Clinical Cardiovascular Disease, 2020, 36 (8): 709-713.

[3] Zhang Tangshuang. The effects of rosuvastatin and atorvastatin on blood lipids and left ventricular ejection fraction in patients with early-onset coronary heart disease and acute myocardial infarction. Cardiovascular disease prevention and treatment knowledge (second half of the month), 2021, 011 (002): 12-14.

[4] Zhao Qilei, Su Pengyu. Research progress on the impact of early Q-wave on the prognosis of acute myocardial infarction. Journal of Hebei Union University (Medical Edition), 2021, 023 (004): 330-333.

[5] Wang Qing, Qi Zhongwen, Xu Shihan, etc. Exploring the Diagnosis and Treatment of Early Coronary Heart Disease from the Perspective of "Upholding the Spirit". Jiangsu Traditional Chinese Medicine, 2023, 55 (7): 7-10.

[6] Arnaout R, Curran L, Zhao Y, et al. An ensemble of neural networks provides expert-level prenatal detection of complex congenital heart disease. Nature medicine, 2021, 27(5): 882-891.

[7] Hill M C, Kadow Z A, Long H, et al. Integrated multi-omic characterization of congenital heart disease. Nature, 2022, 608(7921): 181-191.

[8] Liu A, Diller G P, Moons P, et al. Changing epidemiology of congenital heart disease: effect on outcomes and quality of care in adults. Nature Reviews Cardiology, 2023, 20(2): 126-137.

[9] Morton S U, Quiat D, Seidman J G, et al. Genomic frontiers in congenital heart disease. Nature Reviews Cardiology, 2022, 19(1): 26-42.

[10] Nees S N, Chung W K. The genetics of isolated congenital heart disease. American Journal of Medical Genetics Part C: Seminars in Medical Genetics. Hoboken, USA: John Wiley & Sons, Inc., 2020, 184(1): 97-106.

[11] Sadhwani A, Wypij D, Rofeberg V, et al. Fetal brain volume predicts neurodevelopment in congenital heart disease. Circulation, 2022, 145(15): 1108-1119.

[12] Sliwa K, Baris L, Sinning C, et al. Pregnant women with uncorrected congenital heart disease: heart failure and mortality. Heart Failure, 2020, 8(2): 100-110.

[13] Taksande A, Jameel P Z. Critical Congenital Heart Disease in Neonates: A Review Article. Current Pediatric Reviews, 2021, 17(2): 120-126.

[14] Waern M, Mellander M, Berg A, et al. Prenatal detection of congenital heart disease-results of a Swedish screening program 2013–2017. BMC pregnancy and childbirth, 2021, 21(1): 1-9.

[15] Zimmerman M S, Smith A G C, Sable C A, et al. Global, regional, and national burden of congenital heart disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet Child & Adolescent Health, 2020, 4(3): 185-200.